echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The third domestic company: Jiahe Bio's "Infliximab" is about to be approved

    The third domestic company: Jiahe Bio's "Infliximab" is about to be approved

    • Last Update: 2022-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 17, the official website of NMPA showed that Yuxi Jiahe Biotechnology Co.


    Infliximab is a human-mouse chimeric monoclonal antibody developed by Johnson & Johnson/Mersk that specifically blocks tumor necrosis factor (TNF-α).


    The drug was first approved by the FDA in the United States in 1998, approved in Europe the following year, and approved in China in 2006 under the trade name of Leike®


    Although it has been on the market in China for many years, the first infliximab biosimilar has just been approved in July 2021, from Taizhou Maibotec Pharmaceuticals


    Among several TNF-α antibody drugs, adalimumab is the most competitive as the “Drug King”.


    Competition details of key biosimilars (in Insight database, as of February 17, 2022)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.